/
APLM
$21.24+$0.44 (+2.12%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$45.7M
2M shares
52-week range
$3.66 – $42.12
46% from low
Exchange
NASDAQ
CS
Borrow rate
8.87%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-2918.76
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.8M | $2.0K | $323.0K | $821.0K | $198.0K | $8.5M |
| Cost of revenue | $369.0K | $0 | $0 | $0 | $0 | $0 | $255.0K |
| Gross profit | −$369.0K | $1.8M | $2.0K | $323.0K | $821.0K | $198.0K | $8.2M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.0% |
| R&D | $18.4M | $31.4M | $35.6M | $35.5M | $34.2M | $24.6M | $5.5M |
| Operating income | −$24.7M | −$40.6M | −$50.9M | −$45.1M | −$54.0M | −$42.1M | −$9.5M |
| EBITDA | −$45.3M | −$40.5M | −$50.1M | −$43.9M | −$53.4M | −$41.1M | −$9.2M |
| Net income | −$45.9M | −$74.8M | −$94.8M | −$240.8M | −$172.6M | −$53.9M | −$10.9M |
| Net margin | — | -4070.7% | -4739850.0% | -74554.5% | -21023.3% | -27201.0% | -128.7% |
| EPS (diluted) | -0.53 | -20.70 | -23.45 | -61.60 | -231.99 | -52.80 | -7.57 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-122.00 | $-122.00–$-122.00 | 1 |
| 2027 | $21M | $-138.00 | $-138.00–$-138.00 | 1 |
| 2028 | $13M | $-138.00 | $-138.00–$-138.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Apollomics Inc. Class A Ordinary Shares
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
www.apollomicsinc.com- Employees
- 15
- IPO / List date
- Mar 30, 2023
Held by traders on TradeandTell
No one on the platform currently holds APLM.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in APLM as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-11-25 | 1-for-100reverse |
Recent trades on TradeandTell
No one on the platform has traded APLM yet.
